checkAd

     105  0 Kommentare STAAR Surgical to Report First Quarter Results on May 7, 2024

    STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

    STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants. No access code is required. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

    A taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion for seven days. The replay can be accessed by dialing 877-344-7529 for domestic callers and 412-317-0088 for international callers. Please use access code 3030937. An archived webcast will also be available at www.staar.com.

    About STAAR Surgical

    STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer Lens or “ICL”, which includes the EVO ICL product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com


    The Staar Surgical Stock at the time of publication of the news with a raise of +0,32 % to 43,86EUR on Tradegate stock exchange (26. April 2024, 22:26 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    STAAR Surgical to Report First Quarter Results on May 7, 2024 STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the …